FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017005711> ?p ?o ?g. }

• W2017005711 endingPage "246" @default.
• W2017005711 startingPage "237" @default.
• W2017005711 abstract "High-dose inhaled corticosteroids (ICS) have been associated with the same side-effects as oral corticosteroids. Beclomethasone dipropionate (BDP) and budesonide (BUD) in doses greater than 2000 microg/day are used regularly in severe asthma, despite the fact that safety and efficacy data at such high doses are limited. Fluticasone propionate (FP) has been promoted as being twice as potent clinically as BDP or BUD at doses of 2000 microg/day or less with a similar safety profile. The aim of this study was to compare the efficacy and safety of FP with BDP and BUD in 133 symptomatic adult asthmatics requiring at least 1750 microg/day of BDP or BUD.Patients fulfilling the entry criteria were randomized to receive either their regular ICS medication or FP at approximately half the microgram dose for 6 months in an open, parallel group study. The primary efficacy measure was based on morning peak expiratory flow measurements recorded by patients on daily record cards, while determination of safety was based on a number of endpoints including changes in bone turnover indices, the incidence of topical side-effects and assessments of quality of life.It was shown that patients who were switched to FP, but not those continuing with BDP or BUD, had significant increases in levels of morning serum cortisol and the urine cortisol:creatinine ratio while maintaining asthma control. Serum osteocalcin and the pyridinoline:creatinine ratio, as well as the deoxypyridinoline:creatinine ratio, were also shown to increase only in the FP group. Subjective assessments such as quality of life score, the incidence and ease of bruising, and reports of hoarseness also favoured the FP group.It is concluded that, at the doses studied and with the delivery devices used clinically, FP is at least as effective as BDP/BUD in the management of severe asthma and may offer clinical advantages with respect to steroid-related adverse effects." @default.
• W2017005711 created "2016-06-24" @default.
• W2017005711 creator A5020952868 @default.
• W2017005711 creator A5036891876 @default.
• W2017005711 creator A5048175603 @default.
• W2017005711 creator A5057258487 @default.
• W2017005711 date "2001-09-08" @default.
• W2017005711 modified "2023-10-14" @default.
• W2017005711 title "Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate" @default.
• W2017005711 cites W1756639951 @default.
• W2017005711 cites W1967827648 @default.
• W2017005711 cites W1972488771 @default.
• W2017005711 cites W1987921995 @default.
• W2017005711 cites W1994470802 @default.
• W2017005711 cites W1999493130 @default.
• W2017005711 cites W2000498293 @default.
• W2017005711 cites W2002104195 @default.
• W2017005711 cites W2020874051 @default.
• W2017005711 cites W2032962339 @default.
• W2017005711 cites W2052236120 @default.
• W2017005711 cites W2062949406 @default.
• W2017005711 cites W2069371313 @default.
• W2017005711 cites W2075721622 @default.
• W2017005711 cites W2078706398 @default.
• W2017005711 cites W2094903912 @default.
• W2017005711 cites W2097821130 @default.
• W2017005711 cites W2098109585 @default.
• W2017005711 cites W2099459969 @default.
• W2017005711 cites W2121230694 @default.
• W2017005711 cites W2122478601 @default.
• W2017005711 cites W2148866281 @default.
• W2017005711 cites W2150151407 @default.
• W2017005711 cites W2157477318 @default.
• W2017005711 cites W4248457029 @default.
• W2017005711 cites W5345010 @default.
• W2017005711 doi "https://doi.org/10.1046/j.1440-1843.2001.00329.x" @default.
• W2017005711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11555383" @default.
• W2017005711 hasPublicationYear "2001" @default.
• W2017005711 type Work @default.
• W2017005711 sameAs 2017005711 @default.
• W2017005711 citedByCount "16" @default.
• W2017005711 countsByYear W20170057112012 @default.
• W2017005711 countsByYear W20170057112013 @default.
• W2017005711 countsByYear W20170057112015 @default.
• W2017005711 countsByYear W20170057112016 @default.
• W2017005711 crossrefType "journal-article" @default.
• W2017005711 hasAuthorship W2017005711A5020952868 @default.
• W2017005711 hasAuthorship W2017005711A5036891876 @default.
• W2017005711 hasAuthorship W2017005711A5048175603 @default.
• W2017005711 hasAuthorship W2017005711A5057258487 @default.
• W2017005711 hasConcept C126322002 @default.
• W2017005711 hasConcept C131075544 @default.
• W2017005711 hasConcept C160160445 @default.
• W2017005711 hasConcept C181199279 @default.
• W2017005711 hasConcept C185592680 @default.
• W2017005711 hasConcept C19720800 @default.
• W2017005711 hasConcept C197934379 @default.
• W2017005711 hasConcept C2776042228 @default.
• W2017005711 hasConcept C2776136866 @default.
• W2017005711 hasConcept C2778588143 @default.
• W2017005711 hasConcept C2779028295 @default.
• W2017005711 hasConcept C2780306776 @default.
• W2017005711 hasConcept C2780787237 @default.
• W2017005711 hasConcept C2781212218 @default.
• W2017005711 hasConcept C42219234 @default.
• W2017005711 hasConcept C55493867 @default.
• W2017005711 hasConcept C71924100 @default.
• W2017005711 hasConcept C90924648 @default.
• W2017005711 hasConceptScore W2017005711C126322002 @default.
• W2017005711 hasConceptScore W2017005711C131075544 @default.
• W2017005711 hasConceptScore W2017005711C160160445 @default.
• W2017005711 hasConceptScore W2017005711C181199279 @default.
• W2017005711 hasConceptScore W2017005711C185592680 @default.
• W2017005711 hasConceptScore W2017005711C19720800 @default.
• W2017005711 hasConceptScore W2017005711C197934379 @default.
• W2017005711 hasConceptScore W2017005711C2776042228 @default.
• W2017005711 hasConceptScore W2017005711C2776136866 @default.
• W2017005711 hasConceptScore W2017005711C2778588143 @default.
• W2017005711 hasConceptScore W2017005711C2779028295 @default.
• W2017005711 hasConceptScore W2017005711C2780306776 @default.
• W2017005711 hasConceptScore W2017005711C2780787237 @default.
• W2017005711 hasConceptScore W2017005711C2781212218 @default.
• W2017005711 hasConceptScore W2017005711C42219234 @default.
• W2017005711 hasConceptScore W2017005711C55493867 @default.
• W2017005711 hasConceptScore W2017005711C71924100 @default.
• W2017005711 hasConceptScore W2017005711C90924648 @default.
• W2017005711 hasIssue "3" @default.
• W2017005711 hasLocation W20170057111 @default.
• W2017005711 hasLocation W20170057112 @default.
• W2017005711 hasOpenAccess W2017005711 @default.
• W2017005711 hasPrimaryLocation W20170057111 @default.
• W2017005711 hasRelatedWork W1768592494 @default.
• W2017005711 hasRelatedWork W2027387956 @default.
• W2017005711 hasRelatedWork W2028878266 @default.
• W2017005711 hasRelatedWork W2055935555 @default.
• W2017005711 hasRelatedWork W2069698784 @default.
• W2017005711 hasRelatedWork W2073025986 @default.
• W2017005711 hasRelatedWork W2085176228 @default.

• next